E-viri
Recenzirano
Odprti dostop
-
Papaemmanuil, E; Cazzola, M; Boultwood, J; Malcovati, L; Vyas, P; Bowen, D; Pellagatti, A; Wainscoat, J S; Hellstrom-Lindberg, E; Gambacorti-Passerini, C; Godfrey, A L; Rapado, I; Cvejic, A; Rance, R; McGee, C; Ellis, P; Mudie, L J; Stephens, P J; McLaren, S; Massie, C E; Tarpey, P S; Varela, I; Nik-Zainal, S; Davies, H R; Shlien, A; Jones, D; Raine, K; Hinton, J; Butler, A P; Teague, J W; Baxter, E J; Score, J; Galli, A; Della Porta, M G; Travaglino, E; Groves, M; Tauro, S; Munshi, N C; Anderson, K C; El-Naggar, A; Fischer, A; Mustonen, V; Warren, A J; Cross, N C P; Green, A R; Futreal, P A; Stratton, M R; Campbell, P J
The New England journal of medicine, 10/2011, Letnik: 365, Številka: 15Journal Article
Myelodysplastic syndromes are a diverse and common group of chronic hematologic cancers. The identification of new genetic lesions could facilitate new diagnostic and therapeutic strategies. We used massively parallel sequencing technology to identify somatically acquired point mutations across all protein-coding exons in the genome in 9 patients with low-grade myelodysplasia. Targeted resequencing of the gene encoding RNA splicing factor 3B, subunit 1 (SF3B1), was also performed in a cohort of 2087 patients with myeloid or other cancers. We identified 64 point mutations in the 9 patients. Recurrent somatically acquired mutations were identified in SF3B1. Follow-up revealed SF3B1 mutations in 72 of 354 patients (20%) with myelodysplastic syndromes, with particularly high frequency among patients whose disease was characterized by ring sideroblasts (53 of 82 65%). The gene was also mutated in 1 to 5% of patients with a variety of other tumor types. The observed mutations were less deleterious than was expected on the basis of chance, suggesting that the mutated protein retains structural integrity with altered function. SF3B1 mutations were associated with down-regulation of key gene networks, including core mitochondrial pathways. Clinically, patients with SF3B1 mutations had fewer cytopenias and longer event-free survival than patients without SF3B1 mutations. Mutations in SF3B1 implicate abnormalities of messenger RNA splicing in the pathogenesis of myelodysplastic syndromes. (Funded by the Wellcome Trust and others.).
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.